Passage Bio, Inc.
Market Cap
$23.64M
P/E Ratio
-0.51
EPS
$-14.35
Dividend Yield
0.00%
52-Week Range
$5.12 — $20.00
Volume
13.88K
Avg Volume
57.73K
Beta
1.77
P/E (TTM)
-0.51
Forward P/E
—
PEG Ratio
-3.76
P/S (TTM)
0.00
P/B (TTM)
1.26
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-1.35%
ROA (TTM)
-0.73%
ROIC
—
Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
—
Debt/Equity
1.28
Current Ratio
2.07
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
+0.32%
EPS Growth (5Y)
+0.10%
Sales Growth (3Y)
+0.00%
Sales Growth (5Y)
+0.00%
EPS Est (This Year)
$-6.19
EPS Est (Next Year)
$-2.54
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$14.59
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
3.18M
Float
2.86M
Free Float %
89.90%
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
2020-02-28
Employees
60
CEO
William Chou
Index Membership
—
Website
https://www.passagebio.com
Passage Bio, Inc. (PASG) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $23.64M, a P/E ratio of -0.51, PASG is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare PASG against other stocks using dozens of fundamental and technical filters.
Passage Bio, Inc. (PASG) has a trailing twelve-month (TTM) P/E ratio of -0.51. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Passage Bio, Inc. (PASG) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Passage Bio, Inc. (PASG) has a market capitalization of $23.64 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.